Cargando…

Immune Checkpoint Inhibitors in Pre-Treated Gastric Cancer Patients: Results from a Literature-Based Meta-Analysis

Immunotherapy has recently changed the treatment of several cancers. We performed a literature-based meta-analysis of randomised controlled trials to assess the efficacy of the novel immune checkpoint inhibitors (ICIs) in metastatic gastric cancer. The main outcome was overall survival. Based on age...

Descripción completa

Detalles Bibliográficos
Autores principales: Roviello, Giandomenico, Corona, Silvia Paola, D’Angelo, Alberto, Rosellini, Pietro, Nobili, Stefania, Mini, Enrico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7013524/
https://www.ncbi.nlm.nih.gov/pubmed/31936762
http://dx.doi.org/10.3390/ijms21020448
_version_ 1783496422923960320
author Roviello, Giandomenico
Corona, Silvia Paola
D’Angelo, Alberto
Rosellini, Pietro
Nobili, Stefania
Mini, Enrico
author_facet Roviello, Giandomenico
Corona, Silvia Paola
D’Angelo, Alberto
Rosellini, Pietro
Nobili, Stefania
Mini, Enrico
author_sort Roviello, Giandomenico
collection PubMed
description Immunotherapy has recently changed the treatment of several cancers. We performed a literature-based meta-analysis of randomised controlled trials to assess the efficacy of the novel immune checkpoint inhibitors (ICIs) in metastatic gastric cancer. The main outcome was overall survival. Based on age (cut-off agreed at 65 years), tumour location (gastric vs. gastro-oesophageal junction), programmed death-ligand 1 (PD-L1) status, sex and Eastern Cooperative Oncology Group (ECOG) status (1 vs. 0), we scheduled a subgroup analysis for the overall survival. Three studies were included in the analysis for a total of 1456 cases (811 cases were in the experimental group and 645 cases in the control group). The pooled analysis showed improved overall survival in the experimental arm in the absence of statistical significance (hazard ratio (HR) = 0.87, 95% CI: 0.64–1.18; p = 0.37). The subgroup of patients with PD-L1-positive tumours (HR = 0.82 vs. 1.04) and gastro-oesophageal junction cancer (HR = 0.82 vs. 1.04) showed a statistically significant advantage of overall survival. This study supports the efficacy of immune checkpoint inhibitors in the subgroup of patients with metastatic gastric cancer with PD-L1-positive and gastro-oesophageal junction tumour location. Future studies are needed with the aim of identifying reliable predictive biomarkers of ICI efficacy.
format Online
Article
Text
id pubmed-7013524
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-70135242020-03-09 Immune Checkpoint Inhibitors in Pre-Treated Gastric Cancer Patients: Results from a Literature-Based Meta-Analysis Roviello, Giandomenico Corona, Silvia Paola D’Angelo, Alberto Rosellini, Pietro Nobili, Stefania Mini, Enrico Int J Mol Sci Article Immunotherapy has recently changed the treatment of several cancers. We performed a literature-based meta-analysis of randomised controlled trials to assess the efficacy of the novel immune checkpoint inhibitors (ICIs) in metastatic gastric cancer. The main outcome was overall survival. Based on age (cut-off agreed at 65 years), tumour location (gastric vs. gastro-oesophageal junction), programmed death-ligand 1 (PD-L1) status, sex and Eastern Cooperative Oncology Group (ECOG) status (1 vs. 0), we scheduled a subgroup analysis for the overall survival. Three studies were included in the analysis for a total of 1456 cases (811 cases were in the experimental group and 645 cases in the control group). The pooled analysis showed improved overall survival in the experimental arm in the absence of statistical significance (hazard ratio (HR) = 0.87, 95% CI: 0.64–1.18; p = 0.37). The subgroup of patients with PD-L1-positive tumours (HR = 0.82 vs. 1.04) and gastro-oesophageal junction cancer (HR = 0.82 vs. 1.04) showed a statistically significant advantage of overall survival. This study supports the efficacy of immune checkpoint inhibitors in the subgroup of patients with metastatic gastric cancer with PD-L1-positive and gastro-oesophageal junction tumour location. Future studies are needed with the aim of identifying reliable predictive biomarkers of ICI efficacy. MDPI 2020-01-10 /pmc/articles/PMC7013524/ /pubmed/31936762 http://dx.doi.org/10.3390/ijms21020448 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Roviello, Giandomenico
Corona, Silvia Paola
D’Angelo, Alberto
Rosellini, Pietro
Nobili, Stefania
Mini, Enrico
Immune Checkpoint Inhibitors in Pre-Treated Gastric Cancer Patients: Results from a Literature-Based Meta-Analysis
title Immune Checkpoint Inhibitors in Pre-Treated Gastric Cancer Patients: Results from a Literature-Based Meta-Analysis
title_full Immune Checkpoint Inhibitors in Pre-Treated Gastric Cancer Patients: Results from a Literature-Based Meta-Analysis
title_fullStr Immune Checkpoint Inhibitors in Pre-Treated Gastric Cancer Patients: Results from a Literature-Based Meta-Analysis
title_full_unstemmed Immune Checkpoint Inhibitors in Pre-Treated Gastric Cancer Patients: Results from a Literature-Based Meta-Analysis
title_short Immune Checkpoint Inhibitors in Pre-Treated Gastric Cancer Patients: Results from a Literature-Based Meta-Analysis
title_sort immune checkpoint inhibitors in pre-treated gastric cancer patients: results from a literature-based meta-analysis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7013524/
https://www.ncbi.nlm.nih.gov/pubmed/31936762
http://dx.doi.org/10.3390/ijms21020448
work_keys_str_mv AT roviellogiandomenico immunecheckpointinhibitorsinpretreatedgastriccancerpatientsresultsfromaliteraturebasedmetaanalysis
AT coronasilviapaola immunecheckpointinhibitorsinpretreatedgastriccancerpatientsresultsfromaliteraturebasedmetaanalysis
AT dangeloalberto immunecheckpointinhibitorsinpretreatedgastriccancerpatientsresultsfromaliteraturebasedmetaanalysis
AT rosellinipietro immunecheckpointinhibitorsinpretreatedgastriccancerpatientsresultsfromaliteraturebasedmetaanalysis
AT nobilistefania immunecheckpointinhibitorsinpretreatedgastriccancerpatientsresultsfromaliteraturebasedmetaanalysis
AT minienrico immunecheckpointinhibitorsinpretreatedgastriccancerpatientsresultsfromaliteraturebasedmetaanalysis